MWW hires da Costa as vice president

Share this article:
MWW Group named Dennis da Costa to head its global health policy practice as VP in its East Rutherford, NJ office, with responsibility for the company's work with the Sabin Vaccine Institute and the Global Network for Neglected Tropical Diseases.

Da Costa joins from the International Trachoma Initiative, where he worked on a global advocacy strategy aimed at tackling “diseases of poverty” in the developing world. He previously served as VP, consumer marketing at Fleishman-Hillard, Golin-Harris and Ketchum.

MWW Group president and CEO said da Costa “brings to MWW Group a level of public health specialization entirely uncommon in our industry and a level of expertise absolutely critical if we are to truly help our clients tackle many of the greatest global health challenges facing the world today. I am personally passionate about MWW Group's work in the global health arena.”

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...